<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095641</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000394169</org_study_id>
    <secondary_id>S0225</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <nct_id>NCT00095641</nct_id>
  </id_info>
  <brief_title>S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer</brief_title>
  <official_title>S0225: Phase II Study of Adjuvant Low-Dose Capecitabine After Salvage Surgery in Patients With Locally Recurrent or Persistent Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Giving capecitabine after surgery may&#xD;
      kill any remaining tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well capecitabine works in treating patients who&#xD;
      have undergone surgery for locally recurrent or persistenthead and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine 2-year disease-free survival of patients treated with surgical salvage&#xD;
           followed by adjuvant low-dose capecitabine for locally recurrent or persistent squamous&#xD;
           cell carcinoma of the head and neck .&#xD;
&#xD;
        -  Determine the toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine 2-year overall survival of patients treated with this drug.&#xD;
&#xD;
        -  Determine patterns of disease relapse in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral capecitabine once daily for 12 months in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no longer studying this disease site&#xD;
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Oropharynx</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the head and neck&#xD;
&#xD;
          -  Locoregionally recurrent or persistent disease&#xD;
&#xD;
          -  No thyroid gland, salivary gland, or nasopharynx disease sites&#xD;
&#xD;
          -  Must have undergone definitive or post-operative radiotherapy at the time of initial&#xD;
             curative treatment&#xD;
&#xD;
          -  Must have undergone salvage surgical resection within the past 56 days&#xD;
&#xD;
          -  All current disease must be completely resected, including resection of recurrent&#xD;
             primary disease and/or neck dissection, if regional nodal disease is present&#xD;
&#xD;
          -  Surgical margins must be free of disease on final pathological evaluation of specimens&#xD;
&#xD;
          -  No definitive or adjuvant radiotherapy or reirradiation for recurrent or persistent&#xD;
             disease allowed at the time of salvage treatment&#xD;
&#xD;
          -  No evidence of distant disease by clinical examination and CT scan of the chest and&#xD;
             upper abdomen (including the liver) within the past 90 days&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to take oral tablets OR able to take crushed tablets through a gastrostomy tube&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior systemic chemotherapy as definitive therapy for head and neck cancer allowed&#xD;
             (prior treatment with fluorouracil allowed, but must be catalogued)&#xD;
&#xD;
          -  More than 5 years since prior systemic chemotherapy for any other cancer diagnosis&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy&#xD;
&#xD;
          -  Concurrent hormonal therapy for non-cancer diagnosis allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Schwartz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>November 5, 2004</study_first_submitted>
  <study_first_submitted_qc>November 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2004</study_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

